Search hospitals

>

Illinois

>

Chicago

Ann & Robert H Lurie Children's Hospital of Chicago

Claim this profile

Chicago, Illinois 60611

Global Leader in Brain Tumor

Global Leader in Solid Tumors

Conducts research for Cancer

Conducts research for Leukemia

Conducts research for Acute Lymphoblastic Leukemia

1152 reported clinical trials

83 medical researchers

Photo of Ann & Robert H Lurie Children's Hospital of Chicago in ChicagoPhoto of Ann & Robert H Lurie Children's Hospital of Chicago in ChicagoPhoto of Ann & Robert H Lurie Children's Hospital of Chicago in Chicago

Summary

Ann & Robert H Lurie Children's Hospital of Chicago is a medical facility located in Chicago, Illinois. This center is recognized for care of Brain Tumor, Solid Tumors, Cancer, Leukemia, Acute Lymphoblastic Leukemia and other specialties. Ann & Robert H Lurie Children's Hospital of Chicago is involved with conducting 1,152 clinical trials across 1,422 conditions. There are 83 research doctors associated with this hospital, such as Nobuko Hijiya, MD, Amy Paller, David O. Walterhouse, and Elizabeth A. Sokol.

Area of expertise

1

Brain Tumor

Global Leader

Ann & Robert H Lurie Children's Hospital of Chicago has run 131 trials for Brain Tumor. Some of their research focus areas include:

BRAF positive
Stage IV
Stage II
2

Solid Tumors

Global Leader

Ann & Robert H Lurie Children's Hospital of Chicago has run 100 trials for Solid Tumors. Some of their research focus areas include:

Stage IV
PD-L1 positive
PD-L1 negative

Top PIs

Clinical Trials running at Ann & Robert H Lurie Children's Hospital of Chicago

Brain Tumor

Testicular cancer

Lazy Eye

Acute Myeloid Leukemia

Neuroblastoma

Cancer

Duchenne Muscular Dystrophy

Cystic Fibrosis

Wilms Tumor

Low Grade Glioma

Image of trial facility.

DAY101 vs. Chemotherapy

for Pediatric Brain Cancer

This trial is testing tovorafenib, a medication given alone, in children with a specific type of brain tumor. The drug works by blocking a protein that helps cancer cells grow.

Recruiting

2 awards

Phase 3

Image of trial facility.

Selumetinib vs. Chemotherapy

for Brain Cancer

This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.

Recruiting

2 awards

Phase 3

Image of trial facility.

MAPK Inhibitors + Anti-PD1 Therapy

for Brain Tumors

Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. Unfortunately, some BRAF-altered gliomas can progress or have rebound growth after discontinuation of therapy. Data from BRAFV600E-mutant melanoma has shown potential synergy between MAPK inhibition and anti-programmed cell death 1 (anti-PD1) checkpoint blockade. Anti-PD1 therapy, such as, nivolumab can block the PD1 receptor on T cells, a marker of T cell exhaustion, allowing a continued or more robust anti-tumor immune response. Here, investigators will combine MAPK inhibition with anti-PD1 therapy in recurrent, refractory low grade BRAF-altered glioma and newly diagnosed or recurrent BRAF-altered or NF-altered high grade glioma.

Recruiting

1 award

Phase 1 & 2

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Ann & Robert H Lurie Children's Hospital of Chicago?

Where is Ann & Robert H Lurie Children's Hospital of Chicago located?

Who should I call to ask about financial aid or insurance network?

What insurance does Ann & Robert H Lurie Children's Hospital of Chicago accept?

What awards or recognition has Ann & Robert H Lurie Children's Hospital of Chicago received?